The October 2026 recommendations shift treatment talks in Germany toward time-capped antibiotics, maintenance topicals, and defined roles for isotretinoin, hormonal adjuncts, and two newer topicals. The document is the EuroGuiDerm evidence-based acne guideline, meaning Europe-wide treatment recommendations, updated from 2016 in a 2026 short-version paper by Nast et al.
According to the Journal of the European Academy of Dermatology and Venereology via Wiley, the update covers isotretinoin versus antibiotics, treatment duration, hormonal therapy, and trifarotene and clascoterone in the 2026 short-version paper. For readers, that means discussing an antibiotic stop date, what topical continues afterward, and whether isotretinoin or, for women, hormonal adjuncts fit the acne type. It also means raising contraception and pregnancy plans when those systemic options come up.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the full open-access EuroGuiDerm acne guideline update — Verify the 2026 isotretinoin, antibiotic-duration, hormonal, and new-topical recommendations in the complete paper.
- Download the complete EuroGuiDerm acne long-version guideline PDF — Review detailed evidence, dosing limits, and safety discussion to prepare questions for a clinician visit.
Table of Contents
- What was updated for 2026?
- When does isotretinoin enter the discussion?
- Why are antibiotics shorter and never alone?
- What options can women discuss?
- Where do trifarotene and clascoterone fit?
What was updated for 2026?
The update revisits choices left open after 2016. It weighs systemic isotretinoin against antibiotics, sets expectations for treatment duration, reviews hormonal therapy, and adds trifarotene and clascoterone.
For readers in Germany, the working text is European. The long version is labeled Update 2025 and hosted by the European Dermatology Forum in the Update 2025 long version. German consultations use that European evidence base to frame local prescribing, follow-up, and referral decisions.
When does isotretinoin enter the discussion?
Systemic means taken by mouth to act throughout the body. Isotretinoin is a systemic retinoid option for severe disease that has not settled with other care. The guideline strongly recommends systemic isotretinoin, if possible, for severe papulopustular or moderate nodular acne and for severe nodular or conglobate acne.
Papulopustular means red pimples and pus-filled bumps, nodular means large painful lumps, and conglobate means severe interconnected lumps. For severe papulopustular or moderate nodular disease, the paper cites 0.3-0.5 mg/kg/day. In practice, the talk covers fit, benefit, safety monitoring, and timing. Ask what severity label applies to your acne, why isotretinoin fits now, what blood tests and visits are planned, and what skin, eye, mood, and pregnancy precautions apply during treatment.
Why are antibiotics shorter and never alone?
Antibiotics calm inflammatory acne, but resistance grows with long, solo use. The update therefore pairs every systemic antibiotic course with a non-antibiotic topical, meaning a cream or gel applied to skin that does not rely on antibiotics.
The rule is generally a maximum of 3 months unless specific clinical circumstances justify longer treatment, reaching strong consensus. According to The Derm 5, doxycycline or lymecycline are preferred over minocycline or tetracycline, while routine azithromycin is discouraged for limited efficacy and resistance concerns in the July 29, 2026 summary. Use the first prescription visit to fix the plan in writing:.
- ask for the stop or review date at the start
- ask which non-antibiotic topical pairs with the pill and what continues as maintenance
- ask what triggers a switch to isotretinoin or referral instead of another antibiotic round
What options can women discuss?
Hormonal treatments act as an adjunct alternative, meaning an add-on rather than solo care, for females with severe acne forms. Systemic spironolactone off-label is another adjunct alternative for females with papulopustular, nodular, or conglobate acne, although it is not licensed for acne in Europe.
According to the JEADV Editors Picks July 2026 summary, women can usefully discuss maintenance topicals plus, where eligible, isotretinoin benefits and monitoring or hormonal and spironolactone adjuncts with contraception and pregnancy considerations in the Editors Picks July 2026 summary. That makes cycle history, contraceptive use, pregnancy plans, blood pressure, potassium checks, and interacting medicines relevant to mention early. Ask whether a hormonal adjunct replaces, accompanies, or follows antibiotics and topicals in your case.
Where do trifarotene and clascoterone fit?
Trifarotene is a newer topical retinoid and clascoterone is a topical androgen-receptor inhibitor. Both go on the skin, but they target different acne pathways than benzoyl peroxide or older retinoids.
The update adds recommendations on which acne types and patient groups should receive each drug and with what strength. Head-to-head data against other topicals remain limited, so stronger trials are still needed. Ask which acne type and body area favor one of these topicals for you, how long to test it, and what direct comparison evidence is still missing.